Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus. A clinical trial ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

In this photo illustration, the injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

In the latest trading session, Novo Nordisk (NVO) closed at $69.30, marking a -1.23% move from the previous day.

Novo Nordisk NVO has outperformed the market over the past 5 years by 3.16% on an annualized basis producing an average ...

Novo Nordisk is betting on the future with a $2-billion deal to buy rights to a Chinese obesity drug. But investors remain unimpressed.

In its fourth quarter 2024 investor letter, Polen Global Growth Strategy emphasized stocks such as Novo Nordisk A/S (NYSE:NVO ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...